Structural Requirements for Catalysis, Expression, and Dimerization in the CD26/DPIV Gene Family
- 24 December 2002
- journal article
- research article
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 42 (3) , 694-701
- https://doi.org/10.1021/bi026846s
Abstract
Dipeptidyl peptidase IV (DP-IV/CD26), fibroblast activation protein (FAP), DP-like 1 (DPL1), DP8, DP9, and DPL2 comprise the CD26 gene family. CD26/DP-IV has roles in liver disease, T cell costimulation, chemokine biology, type II diabetes, and tumor biology. DPIV substrates include the glucagonlike peptides, neuropeptide Y, and the chemokines CCL3, CCL5, CCL11, CCL22, and CXCL12. We have proposed that the extracellular region of CD26 is analogous to prolyl oligopeptidase in consisting of an α/β hydrolase domain contributed by both N- and C-terminal portions of the polypeptide and a seven-blade β-propeller domain. Replacing the C-terminal portion of the predicted α/β hydrolase domain of CD26 (residues 501−766) with the homologous portion of DP8 or DP9 produced intact proteins. However, these chimeric proteins lacked dimerization and peptidase activity, suggesting that CD26 dimerization requires the C-terminal portion of the α/β hydrolase domain. Deleting some N-terminal residues of the α/β hydrolase domain of CD26 ablated peptidase activity and greatly diminished cell surface expression. Together with previous data that CD26 peptidase activity requires the C-terminal 20 residues, this suggests that peptidase activity requires the entire α/β hydrolase domain. The catalytic triad of DP8 was shown to be Ser739−Asp 817−His849. Glu259 of DP8, a residue distant from the catalytic triad yet greatly conserved in the CD26 gene family, was shown to be required for peptidase activity. These data concord with our predicted CD26 structure, indicate that biosynthesis of a functional fragment of CD26 is difficult, and confirm the functional homology of DP8 with CD26.Keywords
This publication has 22 references indexed in Scilit:
- Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspectiveBiochemical and Biophysical Research Communications, 2002
- Kinetic Investigation of Chemokine Truncation by CD26/Dipeptidyl Peptidase IV Reveals a Striking Selectivity within the Chemokine FamilyJournal of Biological Chemistry, 2001
- Comodulation of CXCR4 and CD26 in Human LymphocytesJournal of Biological Chemistry, 2001
- The MEROPS Database as a Protease Information SystemJournal of Structural Biology, 2001
- Two highly conserved glutamic acid residues in the predicted β propeller domain of dipeptidyl peptidase IV are required for its enzyme activityPublished by Wiley ,1999
- The Adenosine Deaminase-Binding Region Is Distinct from Major Anti-CD26 mAb Epitopes on the Human Dipeptidyl Peptidase IV(CD26) MoleculeCellular Immunology, 1999
- Regulation of the Receptor Specificity and Function of the Chemokine RANTES (Regulated on Activation, Normal T Cell Expressed and Secreted) by Dipeptidyl Peptidase IV (CD26)-mediated CleavageThe Journal of Experimental Medicine, 1997
- Alterations in Structure and Cellular Localization of Molecular Forms of DP IV/CD26 during T Cell ActivationCellular Immunology, 1996
- Binding of adenosine deaminase to the lymphocyte surface via CD26European Journal of Immunology, 1994
- Triggering of the proteinase dipeptidyl peptidase IV (CD26) amplifies human T lymphocyte proliferationJournal of Cellular Biochemistry, 1991